Stocks › AGIO
Agios Pharmaceuticals, Inc. (AGIO) stock analysis
SKIP 5% confidence · analysed Nov 4, 2026
On Nov 4, 2026, our model rated Agios Pharmaceuticals, Inc. (AGIO) SKIP with 5% confidence at a price of $31.20. That means the signals cancel out; the model sees no clear edge either way.
Technical picture
The 14-day RSI is 51, close to the neutral 50 line, so momentum is balanced.
MACD is below its signal line, so short-term momentum is pointing down.
The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.
Volume is only 0.5x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure: bullish structure intact, no fresh break.
The most recent swing high is $44.09 and the swing low is $29.15; traders often treat these as resistance and support.
Price is sitting in a bullish order block, a zone where large buyers stepped in before.
Fundamentals
The company reports a profit margin of 0.0% and revenue growth of +259.3%.
In its latest quarter it earned $-1.69 per share, which missed the $-1.66 analysts expected, with revenue +259.3% year over year.
Wall Street's average rating is 1.6 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $45.88.
The next earnings report is expected around Nov 5, 2026; prices often move sharply around earnings.
The model's one-paragraph read
No clear edge (SKIP) — composite score -0.05 (SKIP). Technicals: RSI 50.6, MACD bearish, price below SMA50. Fundamentals: margin 0.0%, revenue growth 259.3%. Financial results: YoY revenue +259.3%, last EPS surprise -1.8%, next earnings 2026-11-05. Smart Money Concepts: bullish structure intact, no fresh break, price retesting a bullish order block, price retesting a bearish order block. FinGPT news read: positive. Reference price $31.2; no trade levels (SKIP).
Past ratings for AGIO
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Nov 4, 2026 | SKIP | 5% | $31.20 | — |
"Move since" compares each call's price with the latest analysed price.
Frequently asked questions
Is AGIO a buy right now?
As of Nov 4, 2026, our automated model rates Agios Pharmaceuticals, Inc. (AGIO) SKIP with 5% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
When does Agios Pharmaceuticals, Inc. report earnings next?
The next earnings report is expected around Nov 5, 2026.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.